Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS equivalence trial

Journal of the American College of Cardiology

Volumn 31, Issue 3, 1998, Pages 487-493

  Tebbe, Ulrich ^a   Michels, Rolf ^b   Adgey, Jennifer ^c   Boland, Jean ^d   Caspi, Avi ^e   Charbonnier, Bernard ^f   Windeler, Jürgen ^g   Barth, Hannes ^h   Groves, Robert ^h   Hopkins, Gwyn R ^h   Fennell, William ⁱ   Betriu, Amadeo ^j   Ruda, Mikhail ^k   Mlczoch, Johannes ^l  

^a Orthop Klin   (Germany)

^b CATHARINA HOSPITAL   (Netherlands)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

^d Centre Hospitalier Regional de La Citadelle   (Belgium)

^e KAPLAN HOSPITAL   (Israel)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g Abt fur Med Informatik und B   (Germany)

^h GRÜNENTHAL GMBH   (Germany)

ⁱ Department of Medicine National University of Ireland Cork   (Ireland)

^j HOSPITAL CLÍNIC   (Spain)

^k INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^l GENERAL HOSPITAL LINZ   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO; SARUPLASE; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ALLERGIC REACTION; ANTIGENICITY; ARTICLE; BIOEQUIVALENCE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SURVIVAL RATE;

AGED; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECOMBINANT PROTEINS; STREPTOKINASE; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032032528     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00553-6     Document Type: Article

References (17)

1. Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients . Lancet. 343:1994;311-322.
2. Flohé L. Recombinant human pro-urokinase (non-glycosylated). Drugs Future. 11:1986;851-852.
3. Randomised double blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet. 1:1989;863-868.
4. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT) trial to investigate equivalence . Lancet. 346:1995;329-336.
5. Good Clinical Practice for Trials on Medicinal Products in the EC. Brussels: Commission of the European Community, 1990:III/3976/88-EN.
6. Tebbe U, Windeler J, Boesl I, et al., on behalf of the LIMITS Study Group. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: Influence of heparin on early patency rate (LIMITS study). J Am Coll Cardiol 1995;26:365-73.
7. Acute myocardial infarction pre-hospital and in-hospital management . Eur Heart J. 17:1996;43-63.
8. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
9. Gheorghiade M, Ruzumna P, Borzak S, Havstad S, Ali A, Goldstein S. Decline in the rate of hospital mortality from acute myocardial infarction impact of changing management strategies . Am Heart J. 131:1996;250-256.
10. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction ISIS-2 . Lancet. 2:1988;349-360.
11. ISIS-3 a randomised trial of intravenous streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction . Lancet. 339:1992;753-770.
12. Kleiman NS, White HD, Ohman EM, et al., for the GUSTO Investigators. Mortality within 24 hours of thrombolysis for myocardial infarction: the importance of early reperfusion. Circulation 1994;90:2658-65.
13. Simes RJ, Topol EJ, Holmes DR, et al., for the GUSTO-1 Investigators. Link between the angiography substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-8.
14. Bär FW, Meyer J, Vermeer F, et al., for the SESAM Study Group. Early patency and reocclusion: comparison of saruplase and alteplase in acute myocardial infarction: results of the randomized, multicentre SESAM study (Study in Europe with Saruplase and Alteplase in Myocardial Infarction). Am J Cardiol 1997;79:727-32.
15. GISSI-2 a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction . Lancet. 336:1990;65-71.
16. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). N Engl J Med. 314:1986;1465-1471.
17. Koster RW, Cohen AF, Hopkins GR, et al. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 71:1994;740-744.